Ex Vivo Expansion (ACT-X)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The purpose of this study is to understand how the body's immune cells respond to a new type of vaccine (neoantigen vaccine) designed to help the immune system recognize and fight cancer. To do this, the study team will collect a research specimen from participants to study their immune cells' reactions to the neoantigen vaccine. This research will help researchers learn more about how these vaccines might work to protect or treat against cancer.
Eligibility criteria
Qualifiers
Histologically confirmed current or previous solid malignancy or healthy individuals
Willing to provide mandatory research blood draw or apheresis per protocol
Provide written informed consent
The following laboratory values obtained ≤ 28 days prior to registration
Disqualifiers
IV antibiotic ≤2 weeks prior to apheresis
Major Surgery ≤4 weeks prior to registration
Received a live vaccine ≤30 days prior to registration
Active hematologic malignancies ≤ 3 years prior to registration
Trial design
Treatments tested in this trial
- Blood Draw
- Apheresis
Treatment groups
24 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov